Pharmacoeconomic Guidelines: Baltic (Latvia, Lithuania, Estonia)
Country/Region: Baltic (Latvia, Lithuania, Estonia)
PE Guidelines
Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis) (2002)
PDF in English
PDF in English
Information current as of Tuesday, July 19, 2022
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | PE Guidelines |
| Title and year of the document | Baltic guideline for economic evaluation of pharmaceuticals (Pharmacoeconomic Analysis) (2002) |
| Affiliation of authors | Experts from health authorities of the Baltic countries |
| Purpose of the document | Drug reimbursement and other state funding decisions |
| Standard reporting format included | No |
| Disclosure | Yes |
| Target audience of funding/ author's interests | Pharmaceutical companies. Baltic states’ health authority |
| Perspective | Mainly health care perspective. If relevant, societal |
| Indication | Approved one(s) |
| Target population | Yes |
| Subgroup analysis | Yes |
| Choice of comparator | Most commonly used alternative or practice. Be justified. |
| Time horizon | To model a sufficient analysis period when trial data provide too short a time frame |
| Assumptions required | Not stated |
| Preferred analytical technique | Any one of CMA, CEA, CUA. Need justification. |
| Costs to be included | Only direct health care costs. If relevant, include all costs outside healthcare system, presented separately. |
| Source of costs | Adapt local cost. Be specified. |
| Modeling | Yes, requires details |
| Systematic review of evidences | Encourage meta-analysis |
| Preference for effectiveness over efficacy | Prefer data from RCTs |
| Preferred outcome measure | Change in the health state. Absolute risk difference calculated |
| Preferred method to derive utility | EuroQol, Health Utility Index |
| Equity issues stated | Not stated |
| Discounting costs | Yes, 5% justify for other rates |
| Discounting outcomes | Yes, 5% |
| Sensitivity analysis-parameters and range | Main assumption variables, confidence interval |
| Sensitivity analysis-methods | Details of the statistical tests performed |
| Presenting results | C/E ratio, ICER, total annual cost and benefit |
| Incremental analysis | Yes |
| Total costs vs effectiveness (cost/effectiveness ratio) | Yes |
| Portability of results (Generalizability) | Adjustment needed |
| Financial impact analysis | No |
| Mandatory or recommended or voluntary | |
Acknowledgement: